Navigation Links
Dendreon Announces Proposed Public Offering of Common Stock
Date:12/8/2009

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of 15,000,000 shares of its common stock pursuant to an effective shelf registration statement. Dendreon intends to grant to the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock to cover over-allotments, if any. J. P. Morgan Securities Inc. and Deutsche Bank Securities Inc. will act as joint book-running managers of the offering.

Dendreon intends to use the net proceeds of the offering to fund expenditures in connection with the investment in its manufacturing facilities, including the accelerated build-out of new facilities in Atlanta, Georgia and Orange County, California (providing for additional capacity from such facilities in mid 2011) and build-out of the remaining capacity at its Morris Plains, New Jersey facility, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital.

Dendreon has filed an automatically effective registration statement on Form S-3 relating to the sale of these securities with the Securities and Exchange Commission (the "SEC"). Copies of the preliminary prospectus supplement and related base prospectus for this offering, when available, may be obtained by contacting: J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1-866-803-9204; or Deutsche Bank Securities Inc., Prospectus Depart
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Belmont, MA (PRWEB) May 21, 2013 ... complete tracking to reporting eLearning solution using Tin ... report and dashboard tool. CLD is a leading ... biotech, and medical device companies worldwide. , ... tracking standard that helps learners and trainers more ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... for the 13th consecutive year at the Association ... Conference and Expo. The conference brings together professionals ... technologies. This year’s event will be held from ... The three-day event draws over 1,500 healthcare technology ...
(Date:5/21/2013)... Clinverse, Inc. , a global ... announced today it has formed a strategic alliance ... FLS eClinical commerce platform aggregates data collected through ... ™, Aggregate Spend Solutions’ recently-launched flagship product, is ... transfer of value at investigator meetings or any ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Progress of Ongoing Programmes Confirmed, REINACH and ... presents two clinical posters on its late-stage,investigational antibiotic ... (Verbund Klinische Pharmakologie - VKliPha) which takes place,1-3 ... the conference,further expand the substantial volume of data ...
... major cause of death among men. Based on the ... will be the No. 1 cause of death for ... Universiteit Leuven, in collaboration with the Flemish biotech company ... This substance appears not only to be successful in ...
... the carbon nanotube, a team of researchers has crafted ... material. , Fixed between two electrodes, the vibrating tube ... tunable filter, amplifier and demodulator--to tune in a radio ... through an attached speaker. , Functional across a bandwidth ...
Cached Biology Technology:Arpida Presents Data on Iclaprim at Scientific Congress in Germany 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 3Arpida Presents Data on Iclaprim at Scientific Congress in Germany 4On the road to a new cancer therapy -- starving the tumor 2On the road to a new cancer therapy -- starving the tumor 3World's smallest radio fits in the palm of the hand...of an ant 2World's smallest radio fits in the palm of the hand...of an ant 3
(Date:5/19/2013)... white men and women of European descent inherit common ... toe deformities, including hammer or claw toe. Findings from ... of foot disorders in humansappear in Arthritis Care ... behalf of the American College of Rheumatology (ACR). ... of older adults have foot disorders which may limit ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... population peaks on the edges of the gypsy moth range ... to a team of researchers. , "Slowing the spread of ... the U.S.," says Ottar Bjornstad, associate professor of entomology and ... spread of invasive species is important for successful management." ...
... individuals lacking in B-vitamins ?including college athletes and ... high-intensity exercise and have a decreased ability to ... diets, according to recent Oregon State University research ... and Exercise Metabolism. , The B-vitamins include thiamin, ...
... and his collaborators have resolved key questions regarding transcription, the ... Nobel Prize in Chemistry. , Transcription is the first ... out the out instructions contained in genes. Transcription is carried ... synthesizes an RNA copy of the information in DNA. ...
Cached Biology News:Edge density key to controlling gypsy moth spread 2Poor athletic performance linked to vitamin deficiency 2Nanotech tools yield DNA transcription breakthrough 2Nanotech tools yield DNA transcription breakthrough 3Nanotech tools yield DNA transcription breakthrough 4
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: